---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-120986"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T13:50:14.504846+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer

## Summary
- FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.
- Phase 1 trial planned for 2023, combining MT-601 with front-line chemotherapy.
- New manufacturing process reduces production time from >30 days to 9 days with 90% fewer interventions.
- Interim TACTOPS study data showed multiTAA therapy plus chemo yielded better-than-expected clinical responses.

## SEC filing metadata
- accession: 0001104659-22-120986
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/0001104659-22-120986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/tm2231138d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-120986
- JSON: https://secwatch.observer/filing/0001104659-22-120986.json
- Plain text: https://secwatch.observer/filing/0001104659-22-120986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.